Top

Cancer Cell International

Published in:

Open Access 01-12-2020 | Breast Cancer | Primary research

LncRNA IGBP1-AS1/miR-24-1/ZIC3 loop regulates the proliferation and invasion ability in breast cancer

Authors: Deqin Chen, Yangfan Fan, Fang Wan

Published in: Cancer Cell International | Issue 1/2020

Abstract

Background

Breast cancer (BC) is one of the malignant solid tumors with the highest morbidity in the world. Currently, the therapeutic outcome of different types of treatment can be unsatisfactory. Novel lncRNA biomarkers in BC remains to be further explored.

Methods

Different expression of lncRNAs among BC tissues and adjacent normal tissues were identified with microarray analyses. A series of in vivo and in vitro gain-of-function laboratory procedures were conducted to study the biological functions of IGBP1-AS1. The prognostic effects on IGBP1-AS1 survival were evaluated by using in situ hybridization and survival analysis. In addition, other experiments including RNA pull down analysis, RNA immunoprecipitation, luciferase reporter assays, and chromatin immunoprecipitation as well as validating assays conducted in vivo were applied to identify the target and regulatory mechanisms of IGBP1-AS1.

Results

Significant down-regulation of IGBP1-AS1 was discovered in the cell lines and tissues of BC. With respect to its biological function, overexpression of IGBP1-AS1 had inhibitory effects on the invasion and proliferation of BC cells in vivo as well as in vitro. Analysis of the samples obtained from BC patients indicated a positive effect of IGBP1-AS1 on survival outcomes. LncRNA IGBP1-AS1/miR-24-1/ZIC3 axis as a loop can regulate the proliferation and invasion of BC cells.

Conclusions

IGBP1-AS1 could have inhibitory impact on the invasion and proliferation of BC and may serve as a promising biomarker for BC.

Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today. 2013;49:105–15. https://doi.org/10.1358/dot.2013.49.2.1930525.CrossRefPubMed

Tempero MA. Multidisciplinary management of pancreatic cancer. J Natl Compr Cancer Netw. 2015;13:700–2.CrossRef

Narayan M, et al. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res. 2009;69:2191–4. https://doi.org/10.1158/0008-5472.CAN-08-1056.CrossRefPubMed

Yarmishyn AA, Kurochkin IV. Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet. 2015;6:145. https://doi.org/10.3389/fgene.2015.00145.CrossRefPubMedPubMedCentral

Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41. https://doi.org/10.1016/j.cell.2009.02.006.CrossRef

Jalali S, Kapoor S, Sivadas A, Bhartiya D, Scaria V. Computational approaches towards understanding human long non-coding RNA biology. Bioinformatics. 2015;31:2241–51. https://doi.org/10.1093/bioinformatics/btv148.CrossRefPubMed

Vikram R, Ramachandran R, Abdul KS. Functional significance of long non-coding RNAs in breast cancer. Breast Cancer. 2014;21:515–21. https://doi.org/10.1007/s12282-014-0554-y.CrossRefPubMed

Zhang H, et al. Up-regulation of miR-24-1-5p is involved in the chemoprevention of colorectal cancer by black raspberry anthocyanins. Br J Nutr. 2019;122:518–26. https://doi.org/10.1017/S0007114518003136.CrossRefPubMed

10.

Zhang W, et al. LINC01088 inhibits tumorigenesis of ovarian epithelial cells by targeting miR-24-1-5p. Sci Rep. 2018;8:2876. https://doi.org/10.1038/s41598-018-21164-9.CrossRefPubMedPubMedCentral

11.

Braoudaki M, et al. miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas. Tumour Biol. 2016;37:9887–97. https://doi.org/10.1007/s13277-016-4903-7.CrossRefPubMed

12.

Ma G, Dai W, Sang A, Yang X, Li Q. Roles of ZIC family genes in human gastric cancer. Int J Mol Med. 2016;38:259–66. https://doi.org/10.3892/ijmm.2016.2587.CrossRefPubMed

13.

Yang B, et al. MiR-564 functions as a tumor suppressor in human lung cancer by targeting ZIC3. Biochem Biophys Res Commun. 2015;467:690–6. https://doi.org/10.1016/j.bbrc.2015.10.082.CrossRefPubMed

14.

Koblizek M, Lebedeva A, Fiser K. FlowIO: flow cytometry standard conformance testing, editing, and export tool. Cytometry Part A J Int Soc Anal Cytol. 2018. https://doi.org/10.1002/cyto.a.23563.CrossRef

15.

Dong J, et al. HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clin Cancer Res. 2017;23:3461–73. https://doi.org/10.1158/1078-0432.CCR-16-2180.CrossRefPubMed

16.

Ding W, Ren J, Ren H, Wang D. Long noncoding RNA HOTAIR modulates MiR-206-mediated Bcl-w signaling to facilitate cell proliferation in breast cancer. Sci Rep. 2017;7:17261. https://doi.org/10.1038/s41598-017-17492-x.CrossRefPubMedPubMedCentral

17.

Gokmen-Polar Y, Vladislav IT, Neelamraju Y, Janga SC, Badve S. Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers. Sci Rep. 2015;5:8765. https://doi.org/10.1038/srep08765.CrossRefPubMedPubMedCentral

18.

Milevskiy MJ, et al. Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. Hum Mol Genet. 2016;25:3269–83. https://doi.org/10.1093/hmg/ddw177.CrossRefPubMedPubMedCentral

19.

Li W, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 2016;7:27778–86. https://doi.org/10.18632/oncotarget.8413.CrossRefPubMedPubMedCentral

20.

Luzi E, et al. The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the “Knudson’s second hit”. PLoS ONE. 2012;7:e39767. https://doi.org/10.1371/journal.pone.0039767.CrossRefPubMedPubMedCentral

Title: LncRNA IGBP1-AS1/miR-24-1/ZIC3 loop regulates the proliferation and invasion ability in breast cancer
Authors: Deqin Chen
Yangfan Fan
Fang Wan
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01214-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection

LncRNA SNHG6 enhances the radioresistance and promotes the growth of cervical cancer cells by sponging miR-485-3p

Mesenchymal stem cells derived from iPSCs expressing interleukin-24 inhibit the growth of melanoma in the tumor-bearing mouse model

Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells

Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer